# A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

> **NCT00168324** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 599 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** 700 µg Dexamethasone
- **DRUG:** 350 µg Dexamethasone
- **OTHER:** Sham Injection

## Key facts

- **NCT ID:** NCT00168324
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-01
- **Primary completion:** 2008-03-01
- **Final completion:** 2008-10-01
- **Target enrollment:** 599 (ACTUAL)
- **Last updated:** 2019-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168324, "A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00168324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*